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Pharmacokinetics of long half-life antibacterials* 
F. Follath 
Clinical Pharmacology Division, Department of Medicine, Kantonsspital Basel, Switzerland 
Trimethoprim (TMP), sulfamethoxazole (SMZ) and sulfadiazine (SDZ) are 
characterized by elimination half-lives of 9 to 15 h. Effective serum concen-
trations can therefore be maintained by twice daily administration, but without a 
loading dose steady state levels will be reached only after 3 days. Renal disease has 
little effect on the pharmacokinetics of unchanged SMZ, whereas TMP and SDZ 
elimination is prolonged in uremia. Dosage adaptation to creatinine clearance is 
difficult, since the ratio of the two components in serum and urine will be altered. 
Abnormal drug accumulation in liver disease during a treatment with TMP and 
SMZ has not been demonstrated. 
Die Halbwertszeiten von Trimethoprim (TMP), Sulfamethoxazol (SMZ) und 
Sulfadiazin (SDZ) liegen zwischen 9 und 15 h. Dank dieser 1angsamen 
Elimination konnen therapeutisch wirksame Serumkonzentrationen durch 12-
stiindliche Medikamentengaben aufrecht erhalten werden. Ein 'steady-state' wird 
allerdings erst nach 3 Tagen erreicht, weshalb eine initiale Sattigungsdosis 
erforderlich sein kann. Bei Niereninsuffizienz bleibt die Halbwertszeit des SMZ 
unverandert, wogegen die Elimination des TMP und des SDZ bei Uramie 
verzogert sind. Bei den f1xen TMP/SMZ-Kombinationen ist eine Dosisanpassung 
bei stark verminderter Kreatinin-Clearance problematisch, da das Verhaltnis der 
einzelnen Komponenten infolge ihrer unterschiedlichen Kinetik gegeniiber der 
Norm verandert wird. Eine abnorme Akkumulation dieser Medikamente bei 
Leberkrankheiten wurde hingegen bis jetzt nicht beobachtet. 
Introduction 
A correlation between pharmacodynamic or therapeutic effects and serum concen-
trations has been demonstrated for several drugs. In chemotherapy with reversibly 
acting bacteristatic agents a minimum inhibitory concentration in the blood should 
be reached and maintained for the duration of treatment. Therefore, the choice of 
dosage regimens can become a critical factor for therapeutic success or failure. The 
knowledge of the time course of drug absorption, distribution, metabolism and 
excretion will greatly help the clinician to make rational decisions concerning the 
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optimal dose and dosing interval. Among the different pharmacokinetic parameters 
the elimination half-life (t1), the volume of distribution (Vd) and the fractional 
elimination of unchanged dfug in the urine (fr) are of special interest for calculations 
of dosage schedules in different clinical situations. 
Half-life and drug accumulation 
The elimination half-life, i.e. the time required for the drug level to decrease by 50%, 
gives an indication about the duration of action following a single dose and deter-
mines the course and extent of drug accumulation following repetitive admini-
stration. In the following discussion the half-life during the post-distribution phase 
(/J) is employed, since kinetic data of folate inhibitors were usually analysed by an 
open one compartment model. 
Trimethoprim (TMP) and the sulphonamides in the current antibacterial 
combinations are characterized by considerably longer half-lives than most other 
antibiotics. In subjects with normal renal function the range of mean t1 values was 9 
to 14 h for TMP, 9 to 11 h sulphamethoxazole (SMZ) (Craig & Kunin, 1973; 
Kaplan et al., 1973; Rieder et al., 1974; Zech et al., 1978), 10 to 15 h for sulfadiazine 
(SDZ) (Andreasen et al., 1978; Ohnhaus & Spring, 1975) and 9 to 11 h for sulfa-
moxole (SMO) (Kuhne et al., 1976). The obvious advantage of the relatively slow 
elimination is the possibility to maintain therapeutic serum levels by administration 
every 12 h. Besides being practical, this dosage regimen also prevents abnormal drug 
accumulation. The so called accumulation factor R, i.e. the relationship between 
drug amount in the body at steady state (mss) and the maintenance dose (D), depends 
only on the relative dosing intervale= r/t1 (Kruger-Thiemen, 1960): 
2 
R mss- 1 1 44 / =D-1-2-e ~ · t~r 
Thus, as long as t1 and dosing interval (r) remain in the same range, accumulation 
2 
will not occur to any clinically relevant degree. 
Another practical problem to be considered with slowly eliminated drugs is the 
need for an initial loading dose. Since steady state serum concentration ( Css) will 
only be reached after f1ve half-lives, a treatment starting with a usual maintenance 
dose might be inadequate, when immediate therapeutic action is required. In the 
case oftrimethoprim-sulphonamide combination Css is usually not achieved before 
48 h. While this delay can be accepted in many clinical situations a loading dose 
must be given in patients with renal disease in whom the dosing interval is prolonged 
or the maintenance dose reduced. 
Finally the influence of age on the rate of sulphonamide elimination should be 
remembered. The t1 in infants less than 10 days old is longer than in adults, it then 
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rapidly decreases during the next weeks to remain at a lower level until the age of 6 
to 8 years (Krauer & Dettli, 1969; Krauer, Spring & Dettli, 1968). The recom-
mended dose is therefore proportionally greater for the age group between 6 months 
and 5 years than for adults (Fowle et al., 197 5). 
Modes of elimination 
The main routes of elimination for drugs are renal excretion and hepatic 
metabolism. The relative importance of these mechanisms for different drugs and 
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patient groups can be easily estimated by measuring the fraction of absorbed dose 
which is eliminated unchanged in the urine. This 'renal dose fraction' fr is one of 
the most useful pharmacokinetic parameters, which allows prediction of altered 
drug elimination in renal disease (Dettli & Tschanz, 1976). 
Trimethoprim and sulphonamide elimination depend both on hepatic metab-
olism and renal excretion. Urinary elimination of unchanged drug in patients with 
normal renal function amounts to 53 to 67% for TMP (Craig & Kunin, 1973; 
Kaplan et al., 1973; Rieder et al., 1974), 15-30% for SMZ (Craig & Kunin, 1973; 
Kaplan et al., 1973; Ohnhaus & Spring, 1975), 50 to 54% for SDZ (Andreasen et al., 
1978; Ohnhaus & Spring, 1975) and 34% for SMO (Kuhne et al., 1976). Most of the 
metabolites are pharmacologically inactive. 
An important factor in the renal excretion of these folate inhibitors is the urinary 
pH value. Since the sulphonamides are weak acids (pKa 5·6 to 6·5) their non-ionic 
tubular reabsorption decreases by alkalinisation of the urine, whereas trimetho-
prim is a weak base (pKa 7·3) and its tubular reabsorption decreases by acidification 
of the urine. The half-life of elimination is not significantly modified by urinary pH 
variation, but the relative amounts of active drug in the urine are considerably 
altered (Craig & Kunin, 1973). This factor should therefore be taken into consider-
ation when experimental data are compared. 
Influence of renal and hepatic disease on the pharmacokinetics 
of trimethoprim and sulphonamides 
Impaired kidney function is one of the most frequent causes of abnormal drug 
accumulation. The relationship between the glomerular filtration rate and renal 
excretion has therefore been studied for a great number of drugs (Dettli, 1977). A 
basic assumption in such investigations is, that a linear relationship exists between 
endogenous creatinine clearance (Clcr) and elimination rate constant (k): 
k = knr + a Clcr 
where knr is the rate constant of extrarenal elimination and a a proportionality 
factor. Values for knr and a can be determined for different drugs by measuring 
elimination rate constants in patients with various degrees of clearance reduction. 
The use of elimination rate constant (k) instead of half-life for comparison with renal 
function is preferable, since instead of the simple linear regression line a complex 
hyperbolic curve is found when t1 and Clcr are graphically related. 2 
The influence of renal disease on the pharmacokinetics of the TMP-SMZ 
combination has been studied by several authors (Baethke, Golde & Gahl, 1972; 
Rieder et al., 1974; Zech et al., 1978). As it could be predicted from the low fr value 
for unchanged SMZ, the elimination of this drug was little altered by renal function: 
Half lives in uremic patients were not longer than 13·3 to 18·8 h (means). However, 
the elimination rate of sulphonamide metabolites in patients with creatinine 
clearance below 5 mllmin approached zero and a marked accumulation occurred. In 
these studies the elimination of TMP was found to be defmitely prolonged in cases 
with Clcr below 10 mllmin: mean t1 increased to 26 to 37 h (Rieder et al., 1974; Zech 2 
et al., 1978). The use of SMZ-TMP combination in patients with severe renal 
disease is therefore problematical. Even if a careful dosage reduction according to a 
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Clcr value is attempted, the proportion of the bacteriologically active components 
can be quite different from normal and SMZ metabolites will reach very high levels. 
From a pharmacokinetic point of view sulfadiazine could be a more suitable 
candidate for combination with trimethoprim in the treatment of infections in 
patients with renal disease. Elimination rates of SDZ in cases with different degrees 
of clearance reduction are similar to that ofTMP (Ohnhaus & Spring, 1975; Bergan, 
Vik-Mo, & Anstad, 1977). The ratio ofthe extrarenal elimination rate constant knn 
which is equal to the elimination rate constant in anuric patients, and the overall 
normal elimination rate constant (kn) is about 0·45 for both drugs. Since kn/ kn = Qo 
is also linearly related to creatinine clearance, dosage adaptation in renal disease can 
be performed with simple nomograms (Dettli & Tschanz, 1976). In contrast to 
SMZ-TMP a combination of SDZ-TMP would require a dosage reduction by the 
same proportion for both components. 
The kinetics of trimethoprim and sulphonamides in liver disease have been less 
well investigated than in renal disease. Rieder & Schwartz ( 197 5) found in 7 
patients with advanced liver damage no direct evidence for prolonged elimination of 
SMZ or TMP: the mean half-lives of 10·1 and 14·3 h respectively were similar to that 
in control subjects. Also the ratio of metabolized to unchanged sulphamethoxazole 
remained in the normal range. In a recent study by Neuman & Fluteau (1978) tri-
methoprim and sulphamoxole serum levels following repeated administration to 4 
cases with liver cirrhosis were not significantly different from serum levels in control 
subjects. These studies indicate that administration of antibacterial folate inhibitors 
in patients with liver disease is probably without particular risk of accumulation. 
However, the problem of trimethoprim and sulfonamide metabolism in chronic 
liver disease should be further evaluated. 
The pharmacokinetic properties of sulfonamides and diaminopyrimidines should 
be carefully considered before they are used in f1xed drug combinations. Substances 
with identical kinetic behaviour have the advantage to ensure an optimal serum and 
urinary concentration ratio for ·antibacterial synergism, which is maintained in 
patients with impaired drug elimination mechanisms. 
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Discussion 
Professor Asscher, Cardiff One aspect of clearance of trimethoprim and sulphona-
mide to which Dr Follath did not refer was urine flow rate. Does he think that is of 
importance? I recall that trimethoprim excretion is highly flow rate-dependent, 
whereas the sulphonamide component is not so much affected by urine flow. I 
believe this was shown by Sharpstone (1969). 
Dr Follath. That is right. Flow rate influences the elimination of these drugs, but it 
was shown that this factor is not important clinically. The same applies to urine pH. 
Although Craig & Kunin (1973) have demonstrated that a pH dependent 
elimination clearly exists, the half-lives in the various patient groups were found to 
remain in the same range. This means that urine flow rate will not influence the 
dosage schedule, but it should be considered when pharmacokinetic data from 
different authors are compared. 
Professor Turner, London. Protein binding of those drugs was similar, but the 
volume of distribution was markedly different. Could Dr Follath postulate the 
different factors responsible for the volume of distribution? 
Dr Follath. The volume of distribution is higher with trimethoprim, which may 
indicate that its concentration in the various tissues is also different from that of 
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sulphonamides. The volume of distribution is influenced by different factors, such as 
lipid solubility and speciftc binding affmity of the various tissues. 
Professor Brumfitt. Dr Follath told us that there was no difference in the half-life in 
advanced liver disease and normal liver. Has he studied the liver 'excretion'-if I 
may use that term-either by retrograde endoscopy, puncture of the bile duct at 
operation, duodenoscopy or any of the other techniques? 
Dr Follath. I have not studied any of these drugs myself. The only paper I have 
found on this subject is that by Rieder & Schwartz (1974). They measured serum 
levels in control patients and in patients with liver disease. The techniques 
mentioned by Professor Brumfttt were not used. 
Dr Bergan. The explanation for the higher distribution volume of trimethoprim 
compared to sulphonamides is that trimethoprim penetrates better into the cells of 
the body. 
Dr Follath. This, again, is a consequence of lipid solubility of a drug. Highly lipid 
soluble drugs will obviously penetrate cell membranes better than lipid insoluble 
ones. 
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